Category: Syneron Medical Ltd.
Syneron Medical has a big week with Q4 earnings that beat estimates, a new chief executive and the $15 million acquisition of New Star Lasers and its CoolTouch aesthetic devices.
Israeli device maker Syneron Medical Ltd. (NSDQ:ELOS) made some major moves this month, announcing a new CEO alongside strong Q4 earnings and signing a deal to acquire New Lasers Inc.
Iluminage Beauty, the Syneron Medical & Unilever Ventures joint venture, landed expanded indication from the FDA for its me brand of home-use hair removal systems.
Iluminage Beauty, the joint venture between Unilever Ventures & Syneron Medical Ltd. (NSDQ:ELOS), won expanded indication from the FDA for its "me" brand of home-use hair removal products.
Ali Haghighi-Mood, the former president & CEO of Cambridge Heart, and chairman Roderick de Greef both resign for unnamed reasons.
Cambridge Heart (NSDQ:CAMH) said chairman and interim president Roderick de Greef and former president & CEO Ali Haghighi-Mood have both resigned from the medical device company.
Syneron and Unilever subsidiaries have established a joint venture for home beauty devices, causing Syneron shares to jump by around 16%, this week.
Syneron Medical Ltd. (NSDQ:ELOS) stock surged by 16% for the week after its subsidiary, Syneron Beauty, said it will partner with Unilever Ventures's Iluminage Inc., on a joint venture, to be called Iluminage Beauty.
Syneron wins 510(k) clearance from the FDA and CE Mark approval in the European Union for its VelaShape III device.
Syneron Medical Ltd. (NSDQ:ELOS) said it won a pair of regulatory nods for its VelaShape III "body shaping" device.
Syneron Medical's 2nd-quarter earnings meet Wall Street's expectations, but sales fall short, sending shares down on The Street.
Syneron Medical Ltd. (NSDQ:ELOS) stumbled during the 2nd quarter, posting earnings that were even with Wall Street's forecast but just missing sales expectations, sending share prices down this week.
Israel-based cosmetics company Syneron lands approval in Korea for its Elure melanin-reducing product, a big win in the overall Asian market, which represents 95% of skin-lightening product sales.
Israel-based aesthetic device company Syneron Medical (NSDQ:ELOS) landed Korean regulatory approval for its elure skin-lightening product, a victory the company touts as crucial in a high-demand market.